Shin-Etsu Chemical Develops New Thermal Interface Silicone Rubber Sheet Series for Applications in Components of Electric Vehicles as the Technology for High Voltage Devices Advances
13.4.2022 09:00:00 EEST | Business Wire | Press release
Shin-Etsu Chemical Co., Ltd., (Head Office: Tokyo, President: Yasuhiko Saitoh) has newly developed thermal interface silicone rubber sheet, the “TC-BGI Series,” for applications in components for electric vehicles as the technology for high voltage devices advances.
At present, demand for electric cars is growing, starting with electric vehicles (EV), and going forward, further widespread market growth is expected. The components used in electric cars are required to be smaller and lighter, and to increase energy density, high voltage is required for the system voltage.
In order to meet these requirements, Shin-Etsu Chemical has been going forward with the development of thermal interface silicone materials that can be used as heat dissipation measures for component parts of electric cars for which high voltage requirements are increasing.
This new product, the “TC-BGI Series,” is a high hardness thermal interface silicone rubber sheet that has the combined characteristics of high voltage endurance and thermal conductivity that are achieved by means of our company’s own technologies, and this new product comes in 2 thicknesses: 0.2mm and 0.3mm.
The main characteristics of this new product are as follows:
1. It realizes a voltage endurance assurance that is at the highest level in the industry. We can assure a voltage endurance of 3kV with the thickness of 0.2mm, and 5kV with the thickness of 0.3mm on the entire surface of a sheet. Furthermore, we are in the process of developing a product that will assure more than 4kV voltage endurance with a sheet of 0.2mm thickness on the entire sheet surface.
2. It has high thermal conductivity of 7W/m・K.
3. It possesses high hardness and at the same time high strength, and it is superior in workability compared to the pad-type.
4. Compared to the non-silicone-type, it is superior in long-term reliability.
In order to strengthen an automobile’s performance and reliability, heat dissipation material is essential, and various products and technologies for achieving heat dissipation are being developed.
Shin-Etsu Chemical has a very wide line-up of various types of silicone thermal interface materials. In addition to silicone rubber sheets, we offer pads, greases (oil compounds), gap fillers, liquid rubbers (adhesives and potting material). Our wide variety of silicone thermal interface materials can meet the demand for various heat dissipation measures.
Along with the development of these new products, Shin-Etsu Chemical is moving forward in meeting our customers’ various requests regarding such areas as technical support with thermal analysis technologies, and we are manufacturing and processing at International Standard for Automotive Quality Management Systems (IATF16949:2016)-approved plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412006182/en/
Contact information
For inquiries about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-6812-2340, or from outside Japan: 81-3-6812-2340
Fax: 03-6812-2341, or from outside Japan: 81-3-6812-2341
E-mail: sec-pr@shinetsu.jp
https://www.shinetsu.co.jp/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur ® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 14:00:00 EEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
Infobip Launches PitchMate — An AI Fan Companion for Global Football2.7.2026 13:00:00 EEST | Press release
Global AI-first cloud communications platform Infobip launched PitchMate, a new AI-powered conversational agent that brings football fans closer to the action of the world’s biggest football tournament. Purpose-built for the global football audience, PitchMate joins the TGR Haas F1 Team RaceMate — Infobip’s AI fan engagement solution for the TGR Haas F1 Team — in demonstrating how conversational AI is transforming fan engagement across sports worldwide. RaceMate, launched last April for this year’s motorsport season, is an AI agent on WhatsApp and Apple Messages for Business that puts TGR Haas F1 Team fans at the center of the action. It delivers real-time race data, personalized content, team radio highlights, trivia, and native multilingual support, turning passive viewers into active participants through natural, human-like conversations across every race weekend. Since its launch, RaceMate has reached users in more than 60 countries, achieving more than 40,000 messages exchanged wi
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies2.7.2026 12:00:00 EEST | Press release
Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/ Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies This acquisition brings together two highly compatible areas. Besins Healthcare brings deep expertise in hormone therapies for women’s and men’s health, including treatments such as Estrogel®/Oestrogel® (estradiol)2 and Utrogestan®3 (micronized progesterone) for women, and Androgel®/Testogel®4 (testosterone) for men. UniD contributes advanced capabilities in technologies that can enable more differentiated, less frequentl
ROYC Selected by Slättö as Structuring and Platform Solution for Luxembourg Feeder Fund2.7.2026 11:45:00 EEST | Press release
ROYC, a leading global structuring and platform provider, today announced that Slättö, a Nordic private markets real estate firm, has selected ROYC to establish and manage a Luxembourg-domiciled feeder fund designed to efficiently aggregate individual subscriptions from professional investors. The Luxembourg-domiciled vehicle will be fully structured and administered on ROYC’s proprietary platform, delivering investors a seamless digital experience with real-time portfolio access, automated reporting, and efficient global distribution. ROYC streamlines onboarding and governance, standardizes legal documentation, and broadens access to capital. “Private markets are undergoing a structural shift as global banks and wealth platforms increasingly seek efficient access to high-quality private equity strategies. By combining our deep structuring expertise with ROYC’s digital operating infrastructure, we enable leading managers like Slättö to launch investor-ready vehicles rapidly while deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom